Brief: Protara Therapeutics Granted FDA Fast Track Designation For Intravenous Choline Chloride For Patients Receiving Parenteral Support
21/10/2024 13:40
Oct 21 (Reuters) - Protara Therapeutics Inc TARA.O :
* PROTARA THERAPEUTICS GRANTED FDA FAST TRACK DESIGNATION
FOR
INTRAVENOUS CHOLINE CHLORIDE FOR PATIENTS RECEIVING PARENTERAL
SUPPORT
* PROTARA THERAPEUTICS INC: ON TRACK TO INITIATE
REGISTRATIONAL
THRIVE-3 TRIAL IN 1Q' 2025
Source text for Eikon: ID:nGNX1hjbCL
Further company coverage: TARA.O
Recent news on Protara Therapeutics
See all newsProtara Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Protara Therapeutics Q2 net loss widens on higher expenses
Brief: Protara Therapeutics - Enters Sales Agreement With TD Cowen For Common Stock Offering
Brief: Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses
Protara Therapeutics Q1 net loss widens on higher expenses